CINV Flashcards

1
Q

Patient risk factors for CINV

A
  • Younger age <50y
  • Female
  • Anxiety
  • Hx of chemo-induced CINV
  • Hx of motion sickness
  • Hx of emesis w past pregnancy
  • Hx of low prior chronic alcohol intake (<1 glass per day)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

High emetogenic risk choice of therapy

A

Acute:

  • NK1 antagonist (PO Aprepitant 125mg on D1, followed by 80mg OD on D2, D3) (IV Aprepitant 130mg D1)
  • 5-HT3 antagonist (PO/IV Ondansetron 8-16mg OD D1) (PO/IV Granisetron 1mg OD D1)
  • Or NK1 + 5-HT3 (PO Akynzeo 1 capsule OD D1) - contains Netupitant 300mg and Palonosetron 0.5mg
  • PO/IV Dexamethasone 12mg OD D1, 8mg OD D2-4
  • +/- PO Olanzapine 5-10mg OD D1-4 (consider 2.5mg for elderly)

Delayed:

  • Dexamethasone 8mg OD D2-4
  • Olanzapine 5-10mg OD D2-4
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Mod emetogenic risk choice of therapy

A

Acute:

  • 5-HT3 antagonist (PO/IV Ondansetron 8-16mg OD D1) (PO/IV Granisetron 1mg OD D1)
  • Dexamethasone IV/PO 12mg D1, 8mg OD D2-4

Delayed:

  • Dexamethasone IV/PO 8mg OD D2-4
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Low emetogenic risk choice of therapy

A

Acute:

  • 5HT3 antagonist (PO/IV Ondansetron 8-16mg OD D1) (PO/IV Granisetron 1mg OD D1)

OR

  • Dexamethasone IV/PO 12mg D1 8mg?

OR

  • Dopamine-2 antagonist (PO/IV Metoclopramide 10mg OD-TDS PRN)

Delayed:

NIL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Minimal emetogenic risk choice of therapy

A

NIL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

NK1 antagonist

  • Place in therapy
  • MOA
  • Dosing
  • Adverse effects
  • DDIs
A

Place in therapy

  • acute and delayed CINV

MOA

  • binds to NK-1 receptors, prevents substance P (nociceptive neurotransmitter) from binding to the NK-1 receptor

Dosing

  • PO Aprepitant 125mg OD D1, 80mg OD D2-3
  • IV Aprepitant 130mg OD D1
  • Akynzeo (Netupitant 300mg, Palonosetron 0.5mg) 1 Cap OD, D1

Adverse effects

  • Fatigue
  • Physical weakness
  • Nausea
  • Hiccups
  • Headache

DDIs

*Aprepitant is a CYP3A4 inhibitor and CYP2C9 inducer

  • Steroids (incr conc.)
  • Warfarin (dcr conc.)
  • BZDs (incr conc.)
  • Certain chemotherapy (incr conc. of ifosfamide)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

5-HT3 antagonist

  • Place in therapy
  • MOA
  • Dosing
  • Adverse effects
  • DDIs
A

Place in therapy

  • acute CINV

MOA

  • bind to 5-HT3 receptors on vagus afferent nerves, prevent the transmission of signals to the brain, therefore prevent efferent signals that induce N&V
  • also have 5-HT3 receptor in CTZ

Dosing

  • PO/IV Ondansetron 8-16mg OD D1, 8mg BD D2 onwards
  • PO/IV Granisetron 1mg OD D1, 1mg OM D2 onwards
  • PO Akynzeo (Netupitant 300mg + Palonosetron 0.5mg) 1 Cap OD, D1

Adverse effects

  • Headache
  • Constipation
  • QTc prolongation

DDIs

  • Serotonin syndrome (e.g., w SSRIs)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Dopamine-2 antagonist (Olanzapine)

  • Place in therapy
  • MOA
  • Dosing
  • Adverse effects
  • DDIs
A

Place in therapy

  • Acute, delayed CINV

MOA

  • Block dopamine receptors in CTZ, anticholinergic activity, antagonize of peripheral serotonin receptors in the intestine

Dosing

  • PO Olanzapine 5-10mg OD D1-4 (2.5mg OD in elderly)

Adverse effects

  • Sedation
  • Postural hypotension
  • Anticholinergic SEs (dry mouth, constipation)
  • EPSE - tremors, restlessness, uncontrolled muscle movements

DDIs

  • Not to be used with Metoclopramide due to incr risk of EPSE, neuroleptic malignant syndrome, tardive dyskinesia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Dopamine-2 antagonist (Metoclopramide)

  • Place in therapy
  • MOA
  • Dosing
  • Adverse effects
  • DDIs
A

Place in therapy

  • Acute, breakthrough

MOA

  • Block dopamine receptors in CTZ, stimulate cholinergic activity in the gut to incr gut motility, antagonize of peripheral serotonin receptors in the intestine

Dosing

  • Metoclopramide 10mg OD-TDS PRN

Adverse effects

  • Sedation
  • Diarrhea
  • QTc prolongation
  • EPSE - tremors, restlessness, uncontrolled muscle movements

DDIs

  • Not to be used with Olanzapine due to incr risk of EPSE
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Dexamethasone

  • Place in therapy
  • MOA
  • Dosing
  • Adverse effects
  • DDIs
A

Place in therapy

  • Acute and delayed CINV

MOA

  • activity in CNS

Dosing

  • PO/IV Dexamethasone 12mg OD D1, 8mg OD D2-4

Adverse effects

  • GI upset (stomach pain)
  • Insomnia
  • Weight gain, water retention
  • Easy bruising
  • Anxiety
  • Elevations in glucose
  • (rare) Psychosis, hyperactivity
  • (rare) Reactivation of stomach ulcers

*May prescribe Famotidine or Omeprazole (20mg OD)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Benzodiazepines

  • Place in therapy
  • MOA
  • Dosing
  • Adverse effects
  • DDIs
A

Place in therapy

  • Anticipatory

MOA

  • Bind to BZD receptor on postsynaptic GABA neuron, enhance GABA inhibitory effect leading to depression of vomiting center

Dosing

  • Lorazepam 0.5-2mg 30min before chemotherapy (or on the night before treatment, then repeated the next day 1-2h before tx)
  • Alprazolam 0.5-1mg 30min before chemotherapy

Adverse effects

  • Sedation
  • Hypotension
  • Unstable, clumsy
  • Memory loss
  • Abnormal sleep behavior
  • Paradoxical excitement - excitement, agitation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Other adjuncts

A

Refractory CINV

E.g.,

  • Haloperidol

PO/IV Haloperidol 0.5-2mg q4-6h

  • Prochlorperazine/Chlorpromazine/Promethazine

PO Prochlorperazine 10mg TDS/QDS PRN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Non-pharmacological for CINV

A
  • Small frequent meals, avoid heavy meals
  • Avoid greasy, spicy, very sweet/salty food, food with strong flavors and smells
  • Sip small amounts of fluid
  • Avoid caffeinated beverages
  • Avoid lying flat for 2h after eating
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Non-pharmacological for prevention of anticipatory CINV

A
  • Behavioral therapy (listen to music, relaxation, hypnosis)
  • Acupuncture/acupressure
  • Ginger
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Checkpoint inhibitors

A

CPIs (e.g., pembrolizumab) have minimal emetogenic risk and do not require routine use of prophylactic antiemetics

If CPI added to chemotherapy, follow emetogenic risk of the other agents administered, Dexamethasone should not be emitted

How well did you know this?
1
Not at all
2
3
4
5
Perfectly